ArticleBrain : a journal of neurology2019
Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson's disease.
Article in Brain : a journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Dopamine D2-receptor blockade in humans disrupts the effect of effort on learning.PLoS biology · 2026Trial
- Pharmacological and pupillary evidence for the noradrenergic contribution to reinforcement learning in Parkinson's disease.Communications biology · 2025Trial
- Dopamine depletion in Parkinson's increases directed but not random exploration.Science advances · 2026Article
- Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations.Acta pharmaceutica Sinica. B · 2026Review
- The relationship between anxious traits and learning about changes in stochasticity and volatility.PLoS computational biology · 2025Article
- Estimation-uncertainty affects decisions with and without learning opportunities.Nature communications · 2025Article
- Differentiating Reinforcement Learning and Episodic Memory in Value-Based Decisions in Parkinson's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Dopaminergic therapy disrupts decision-making in impulsive-compulsive Parkinsonian patients.Annals of clinical and translational neurology · 2025Article
- Deepening the decisional processes under value-based conditions in patients affected by Parkinson's disease: A comparative study.Cognitive, affective & behavioral neuroscience · 2024Article
- The roots of polarization in the individual reward system.Proceedings. Biological sciences · 2024Article
- Decision-making under ambiguity and risk and executive functions in Parkinson's disease patients: A scoping review of the studies investigating the Iowa Gambling Task and the Game of Dice.Cognitive, affective & behavioral neuroscience · 2023Article
- Impulse control disorder in Parkinson's disease is associated with abnormal frontal value signalling.Brain : a journal of neurology · 2023Article
- The shadowing effect of initial expectation on learning asymmetry.PLoS computational biology · 2023Article
- Article
- Regulation of Cdc42 signaling by the dopamine D2 receptor in a mouse model of Parkinson's disease.Aging cell · 2022Article
- Does insufficient sleep affect how you learn from reward or punishment? Reinforcement learning after 2 nights of sleep restriction.Journal of sleep research · 2021Article
- Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson's disease.Molecular medicine (Cambridge, Mass.) · 2021Review
- Recovering Reliable Idiographic Biological Parameters from Noisy Behavioral Data: the Case of Basal Ganglia Indices in the Probabilistic Selection Task.Computational brain & behavior · 2021Article
- Toward a Computational Neuropsychology of Cognitive Flexibility.Brain sciences · 2020Review
- Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype.Brain : a journal of neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reduced levels of dopamine in Parkinson's disease contribute to changes in learning, resulting from the loss of midbrain neurons that transmit a dopaminergic teaching signal to the striatum. Dopamine medication used by patients with Parkinson's disease has previously been linked to behavioural changes during learning as well as to adjustments in value-based decision-making after learning. To date, however, little is known about the specific relationship between dopaminergic medication-driven differences during learning and subsequent changes in approach/avoidance tendencies in individual patients. Twenty-four Parkinson's disease patients ON and OFF dopaminergic medication and 24 healthy controls subjects underwent functional MRI while performing a probabilistic reinforcement learning experiment. During learning, dopaminergic medication reduced an overemphasis on negative outcomes. Medication reduced negative (but not positive) outcome learning rates, while concurrent striatal blood oxygen level-dependent responses showed reduced prediction error sensitivity. Medication-induced shifts in negative learning rates were predictive of changes in approach/avoidance choice patterns after learning, and these changes were accompanied by systematic striatal blood oxygen level-dependent response alterations. These findings elucidate the role of dopamine-driven learning differences in Parkinson's disease, and show how these changes during learning impact subsequent value-based decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.